Clinical Trial Update: HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission [Phase 2]

View source ↗

Summary

This Phase 2 trial update describes the ctDNA-guided adaptive study 'HERizon-Breast' evaluating sequential anti-HER2 therapies with CNS prophylaxis in HER2-posi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Breast Cancer, HER2-positive Breast Cancer | Phase 2 | Status: RECRUITING